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Though rare, long term use of phenytoin has been associated
with various lymphatic system disorders like pseudolymphoma,
Hodgkin lymphoma and non Hodgkin lymphoma.1 Histopatholog-
ical changes in phenytoin induced lymphadenopathy may be
heterogenous and non speciﬁc as well.2 Phenytoin induced pseudo
lymphoma syndrome may show histopathological ﬁndings similar
to mycosis fungoides and may take a prolonged course even after
the cessation of the drug.3 This case report is about the
development of granulomatous lymphadenopathy secondary to
long term use of phenytoin, which regressed completely after
discontinuation of the drug. The case is being reported because
granulomatous pathology may lead to misdiagnosis and manage-
ment issues if not correlated with phenytoin therapy in such
instances.
2. Case report
59-Year-old female patient was admitted with one episode of
generalized convulsions. She was diagnosed to have epilepsy 7
years back and was taking phenytoin sodium 300 mg per day. She
discontinued medical follow up for seizures and continued to take
the drug. She was admitted with the history of seizures and at that
time noticed to have swellings in the sub-mandibular region
bilaterally measuring about 3 cm  3 cm. Her relatives have
noticed the swelling for the past 4 years and had not taken any
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http://dx.doi.org/10.1016/j.seizure.2012.12.005treatment for the same (Fig. 1). There was no fever, signiﬁcant
weight loss or other constitutional symptoms. She did not give
history of any major illness in the past except for seizures and a
traumatic fracture of the femur. There was no history of
tuberculosis in her family. A blood examination revealed no
abnormality in cell counts, peripheral smear; liver and renal
function tests and serum calcium levels. A chest X-ray revealed
mediastinal widening possibly secondary to hilar adenopathy.
Ultrasound abdomen did not reveal any organomegaly or
paraaortic lymphnode enlargement .The tuberculin test was
negative. An open biopsy of the submandibular node was
performed. Phenytoin sodium was replaced by oxcarbamazepine.
She was not given any antibiotics, steroids or antituberculous
therapy. The lady was discharged, and reviewed after 2 weeks. The
submandibular lymph nodes showed signiﬁcant reduction in size,
and they completely disappeared over a period of six weeks .TheFig. 1. Photograph of the patient showing submandibular adenopathy while on
phenytoin.
vier Ltd. All rights reserved.
Fig. 2. Lymph node bearing multiple epitheloid granulomas with multinucleated
giant cells.
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lymph node architecture by multiple coalescent granulomas
composed of epitheloid histiocytes with scattered multinucleated
giant cells. No deﬁnite evidence of caseous necrosis was seen. She
was followed up for 6 months and never had recurrence of
lymphadenopathy. The chest X-ray also became normal on follow
up.
3. Discussion
Though there are several types of histological features
described in the literature associated with phenytoin induced
lymphadenopathy, granulomatous adenopathy mimicking tuber-
culosis is rare. This patient never received antituberculous
treatment or steroids, but the lymphadenopathy subsided
completely on stopping the phenytoin, which also indicates the
role of phenytoin in producing this pathology. Immunohistological
studies for lymphoma were not carried out due to ﬁnancial
constraints and the patient became symptom free after stopping
phenytoin.
One study which described histopathology of 25 cases of
phenytoin induced lymphadenopathy summarizes their results as
follows: 15 of 25 cases showed a benign histology, which were
classiﬁed according to the presence or absence of immunoblastic
hyperplasia.2 Seven cases were non-Hodgkin lymphoma, and three
were Hodgkin disease. In two of the ﬁve cases for which sequential
biopsies were available for review, histology had progressed from
paracortical hyperplasia to malignant lymphoma.2 There are
several reports of phenytoin induced appearances of cutaneousdermal inﬁltrate. The cutaneous nodules resolved within 2 weeks
after discontinuation of phenytoin therapy.
Phenytoin induced hypersensitivity syndrome can also develop
in some cases which were characterized by the development of
fever, rash, lymphadenopathy, and hepatitis associated with
leukocytosis and eosinophilia.4 Pseudo lymphoma syndrome
(PLS), another important side effect of phenytoin is relatively rare
but can lead to death if there are extensive skin lesions, severe
hepatitis, agranulocytosis and neutropenia.5,6 PLS may also give
rise to harmful effects if misdiagnosed as malignant lymphoma.7
This can also occur with other drugs like, phenobarbitone and
carbamazepine. Histopathologic features of PLS can mimic mycosis
fungoids.7 During the acute phase of the phenytoin induced
pseudolymphoma syndrome, the patient appears immunologically
depressed.3
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